Fred Alger Management’s Viking Therapeutics VKTX Stock Holding History

Fred Alger Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-71,569	Closed	-$2.88M	–	479
2024 Q4	$2.88M	Sell	71,569 -417,300	-85%	-$23.8M	0.01%	298
2024 Q3	$31M	Sell	488,869 -78,415	-14%	-$4.6M	0.15%	105
2024 Q2	$30.1M	Buy	567,284 +100,068	+21%	+$6.56M	0.15%	98
2024 Q1	$38.3M	Buy	+467,216	New	+$20.8M	0.19%	100
2023 Q2	–	Sell	-26,597	Closed	-$443K	–	575
2023 Q1	$443K	Buy	+26,597	New	+$275K	﹤0.01%	408
2019 Q2	–	Sell	-68,000	Closed	-$676K	–	563
2019 Q1	$676K	Buy	68,000 +40,000	+143%	+$335K	﹤0.01%	356
2018 Q4	$214K	Sell	28,000 -7,000	-20%	-$83.7K	﹤0.01%	379
2018 Q3	$610K	Buy	+35,000	New	+$417K	﹤0.01%	348

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Fred Alger Management's VKTX Position: Q1 2025 in Review

Fred Alger Management sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 71,569 shares — an estimated $2.88M sold.

Fred Alger Management first reported a position in VKTX in Q3 2018 and held it in 8 quarters. The position peaked at $38.3M in Q1 2024. 373 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

Fred Alger Management reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
Fred Alger Management sold 71,569 Viking Therapeutics shares in Q1 2025, an estimated $2.88M.
Fred Alger Management first reported a position in Viking Therapeutics in Q3 2018 and held it in 8 quarters.
Fred Alger Management's Viking Therapeutics position peaked at $38.3M in Q1 2024.
373 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Fred Alger Management's 13F filing for Q1 2025, filed 16 May 2025.